Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

319 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Factors associated with high costs of patients with metabolic dysfunction-associated steatotic liver disease: an observational study using the French CONSTANCES cohort.
Ossima AN, Brzustowski A, Paradis V, Van Beers B, Postic C, Laouénan C, Pol S, Castéra L, Gautier JF, Czernichow S, Vallet-Pichard A, Larger E, Serfaty L, Zins M, Valla D, Zaleski ID. Ossima AN, et al. Among authors: castera l. Clin Diabetes Endocrinol. 2024 Apr 25;10(1):9. doi: 10.1186/s40842-023-00163-4. Clin Diabetes Endocrinol. 2024. PMID: 38659082 Free PMC article.
Prospective head-to-head comparison of non-invasive scores for diagnosis of fibrotic MASH in patients with type 2 diabetes.
Castera L, Garteiser P, Laouenan C, Vidal-Trécan T, Vallet-Pichard A, Manchon P, Paradis V, Czernichow S, Roulot D, Larger E, Pol S, Bedossa P, Correas JM, Valla D, Gautier JF, Van Beers BE; QUID NASH investigators. Castera L, et al. J Hepatol. 2024 Aug;81(2):195-206. doi: 10.1016/j.jhep.2024.03.023. Epub 2024 Mar 27. J Hepatol. 2024. PMID: 38548067
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.
Harrison SA, Bedossa P, Guy CD, Schattenberg JM, Loomba R, Taub R, Labriola D, Moussa SE, Neff GW, Rinella ME, Anstee QM, Abdelmalek MF, Younossi Z, Baum SJ, Francque S, Charlton MR, Newsome PN, Lanthier N, Schiefke I, Mangia A, Pericàs JM, Patil R, Sanyal AJ, Noureddin M, Bansal MB, Alkhouri N, Castera L, Rudraraju M, Ratziu V; MAESTRO-NASH Investigators. Harrison SA, et al. Among authors: castera l. N Engl J Med. 2024 Feb 8;390(6):497-509. doi: 10.1056/NEJMoa2309000. N Engl J Med. 2024. PMID: 38324483 Clinical Trial.
Performance of spleen stiffness measurement to rule out high-risk varices in patients with porto-sinusoidal vascular disorder.
Moga L, Paradis V, Ferreira-Silva J, Gudavalli K, Indulti F, Dajti E, Nicoara-Farcau O, Tosetti G, Antonenko A, Fodor A, Vidal-González J, Turco L, Capinha F, Elkrief L, Monllor-Nunell T, Goria O, Balcar L, Lannes A, Mallet V, Poujol-Robert A, Thabut D, Houssel-Debry P, Wong YJ, Ronot M, Vilgrain V, Rampally SP, Payancé A, Castera L, Reiberger T, Ferrusquía-Acosta J, Noronha Ferreira C, Vitale G, Simon-Talero M, Procopet B, Berzigotti A, Caccia R, Turon F, Schepis F, Ravaioli F, Colecchia A, Valsan A, Macedo G, Plessier A, Rautou PE; ERN RARE-LIVER; a study of VALDIG, an EASL consortium. Moga L, et al. Among authors: castera l. Hepatology. 2025 Feb 1;81(2):546-559. doi: 10.1097/HEP.0000000000001004. Epub 2024 Jul 2. Hepatology. 2025. PMID: 38954825
acFibroMASH Index for the Diagnosis of Fibrotic MASH and Prediction of Liver-related Events: An International Multicenter Study.
Feng G, Mózes FE, Ji D, Treeprasertsuk S, Okanoue T, Shima T, Liang H, Tsochatzis E, Chen J, Schattenberg JM, Labenz C, Mahadeva S, Chan WK, Chi X, Delamarre A, de Lédinghen V, Petta S, Bugianesi E, Hagström H, Boursier J, Calleja JL, Goh GB, Gallego-Durán R, Sanyal AJ, Fan JG, Castéra L, Lai M, Harrison SA, Romero-Gomez M, Kim SU, Zhu Y, Ooi G, Shi J, Yoneda M, Nakajima A, Zhang J, Lupsor-Platon M, Zhong B, Cobbold JFL, Ye CY, Eddowes PJ, Newsome P, Li J, George J, He F, Song MJ, Tang H, Fan Y, Jia J, Xu L, Lin S, Li Y, Lu Z, Nan Y, Niu J, Yan X, Zhou Y, Liu C, Deng H, Ye Q, Zeng QL, Li L, Wang J, Yang S, Lin H, Lee HW, Yip TC, Fournier-Poizat C, Wong GL, Pennisi G, Armandi A, Liu WY, Shang Y, de Saint-Loup M, Llop E, Teh KKJ, Lara-Romero C, Asgharpour A, Mahgoub S, Chan MS, Canivet CM, Ji F, Xin Y, Chai J, Dong Z, Targher G, Byrne CD, He N, Mi M, Ye F, Wong VW, Pavlides M, Zheng MH. Feng G, et al. Among authors: castera l. Clin Gastroenterol Hepatol. 2024 Oct 2:S1542-3565(24)00863-2. doi: 10.1016/j.cgh.2024.07.045. Online ahead of print. Clin Gastroenterol Hepatol. 2024. PMID: 39362618
Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux GP, Sibert A, Bouattour M, Lebtahi R, Allaham W, Barraud H, Laurent V, Mathias E, Bronowicki JP, Tasu JP, Perdrisot R, Silvain C, Gerolami R, Mundler O, Seitz JF, Vidal V, Aubé C, Oberti F, Couturier O, Brenot-Rossi I, Raoul JL, Sarran A, Costentin C, Itti E, Luciani A, Adam R, Lewin M, Samuel D, Ronot M, Dinut A, Castera L, Chatellier G; SARAH Trial Group. Vilgrain V, et al. Among authors: castera l. Lancet Oncol. 2017 Dec;18(12):1624-1636. doi: 10.1016/S1470-2045(17)30683-6. Epub 2017 Oct 26. Lancet Oncol. 2017. PMID: 29107679 Clinical Trial.
Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials.
Harrison SA, Wong VW, Okanoue T, Bzowej N, Vuppalanchi R, Younes Z, Kohli A, Sarin S, Caldwell SH, Alkhouri N, Shiffman ML, Camargo M, Li G, Kersey K, Jia C, Zhu Y, Djedjos CS, Subramanian GM, Myers RP, Gunn N, Sheikh A, Anstee QM, Romero-Gomez M, Trauner M, Goodman Z, Lawitz EJ, Younossi Z; STELLAR-3; STELLAR-4 Investigators. Harrison SA, et al. J Hepatol. 2020 Jul;73(1):26-39. doi: 10.1016/j.jhep.2020.02.027. Epub 2020 Mar 6. J Hepatol. 2020. PMID: 32147362 Clinical Trial.
319 results